Serotonin syndrome and neuroleptic malignant syndrome

Overview

[1]

The three drug-induced hyperthermia syndromes — serotonin syndrome (SS), neuroleptic malignant syndrome (NMS) and malignant hyperthermia (MH) — are the classic fellowship "viva triumvirate". They share a final common pathway of central nervous system disturbance, autonomic instability, neuromuscular excitation (rigidity or hyper-reflexia) and uncontrolled heat production, but they differ fundamentally in mechanism, trigger, onset, neuromuscular signature and specific therapy. Confusing them is dangerous: giving cyproheptadine (a serotonergic) to a patient with NMS is useless; giving an antipsychotic (the NMS treatment adjunct for dopamine restoration... which is wrong — antipsychotics CAUSE NMS) to a serotonergic patient worsens them; and giving dantrolene to a patient with pure serotonin syndrome is ineffective — dantrolene is reserved for the rigidity-driven syndromes (NMS and MH). The discriminator that anchors every viva answer is onset and rigidity pattern.[1][7][10]

Pathophysiology — why each syndrome looks the way it does

A mechanistic grasp separates a candidate who memorises tables from one who understands. All three syndromes ultimately produce uncontrolled muscle activity and/or central thermoregulatory disturbance, but the receptor and the location of the defect differ.[4][9][6]

Serotonin syndrome — 5-HT excess in the central nervous system

Serotonin (5-hydroxytryptamine, 5-HT) is synthesised from tryptophan via tryptophan hydroxylase and aromatic L-amino acid decarboxylase, stored in vesicles and released into the synaptic cleft, where it acts at seven families of receptor (5-HT1–5-HT7). The clinically important receptors are 5-HT1A (anxiolytic, antidepressant effects, central), 5-HT2A (the receptor most responsible for the neuromuscular and autonomic features of serotonin toxicity — clonus, hyperreflexia, myoclonus) and 5-HT3 (peripheral, triggers nausea and vomiting — hence ondansetron works here). Serotonin is cleared by reuptake (via the serotonin transporter, SERT) and metabolism by monoamine oxidase A (MAO-A) to 5-hydroxyindoleacetic acid (5-HIAA).[4]

Serotonin syndrome arises when excess 5-HT saturates the synaptic cleft — most classically by combining a drug that increases serotonin release/availability with one that blocks its metabolism or reuptake. The classic deadly pairing is an SSRI/SNRI/clomipramine + an MAOI (the SSRI blocks reuptake, the MAOI blocks metabolism — both pathways of clearance are closed). Other combinations that close the system: tramadol (weak serotonin reuptake inhibitor + opioid) plus an SSRI; linezolid (a reversible, non-selective MAOI antibiotic) plus an SSRI; methylene blue (a potent MAOI used in vasoplegia/met-Hb) plus an SSRI; fentanyl plus an MAOI; and meperidine/pethidine plus an MAOI. The result is over-stimulation of brainstem and spinal cord 5-HT2A receptors → clonus (spinal 5-HT2A), myoclonus, hyperreflexia (especially lower limbs — the spinal cord has the densest serotonergic innervation to the lower motor neuron pool), autonomic instability (brainstem), agitation and hyperthermia. The clonus and hyperreflexia are directly the clinical fingerprint of 5-HT2A over-activation in the spinal cord.[1][4][11]

Neuroleptic malignant syndrome — sudden dopamine withdrawal/blockade

Dopamine is the key inhibitory neurotransmitter in the hypothalamus (thermoregulation) and the basal ganglia (motor control), and a major regulator of sympathetic outflow. Dopamine antagonists — typical antipsychotics (haloperidol, chlorpromazine), atypicals (olanzapine, risperidone, clozapine, quetiapine, ziprasidone, aripiprazole), and the antiemetic dopamine antagonists (metoclopramide, prochlorperazine, promethazine, droperidol) — block D2 receptors. NMS is an idiosyncratic, dose-independent, hyporesponsive-state that occurs when D2 blockade in the hypothalamus and basal ganglia is sudden or profound (rapid dose escalation, depot injection, withdrawal of a dopamine agonist in Parkinson's, or simply high-potency neuroleptic use in a susceptible patient).[2][9]

The loss of hypothalamic dopaminergic tone produces unregulated heat production and altered set-point; the loss of basal ganglia dopaminergic tone produces lead-pipe rigidity (the extrapyramidal extreme) with reflex suppression; and the loss of brainstem dopaminergic modulation produces mutism, stupor and autonomic lability. The muscle rigidity generates heat directly (muscle is the body's main heat source), and sustained contraction causes rhabdomyolysis, CK elevation, hyperkalaemia, AKI and DIC — the downstream consequences that drive mortality. The bradyreflexia/hyporeflexia of NMS (in contrast to the hyperreflexia of SS) reflects the extrapyramidal (rigidity-dominant) rather than spinal origin of the motor disturbance.[9][10]

Malignant hyperthermia — a pharmacogenetic calcium storm

Malignant hyperthermia is genetically and mechanistically distinct. It is an autosomal dominant pharmacogenetic disorder of skeletal muscle (in ~70–80% of cases due to mutations in the ryanodine receptor type 1 gene, RYR1, on chromosome 19q13; in ~1% due to the dihydropyridine receptor gene, CACNA1S; the remainder are unidentified loci). The ryanodine receptor is the calcium-release channel of the sarcoplasmic reticulum of skeletal muscle. When triggered by a potent volatile anaesthetic (halothane — historical; sevoflurane, desflurane, isoflurane — current) or succinylcholine (the depolarising neuromuscular blocker), the mutant RYR1 channel opens inappropriately and fails to close, causing uncontrolled efflux of calcium from the sarcoplasmic reticulum into the myoplasm. The result is sustained, forceful muscle contraction, massive ATP consumption (by the SERCA pump and the contractile apparatus), accelerated aerobic and anaerobic metabolism → hypercapnia, hyperthermia and lactate — and ultimately rhabdomyolysis, hyperkalaemia and disseminated intravascular coagulation.[6][8]

The clinical fingerprint is refractory hypercapnia (rising end-tidal CO₂ despite increasing minute ventilation — the single earliest and most specific sign), generalised or masseter (jaw) rigidity, tachycardia and rapidly rising temperature, with mottled skin, sweating and rhabdomyolysis. MH occurs in the operating theatre or shortly after anaesthesia (rarely, exercise- or heat-induced "awake MH" variants exist), with onset minutes to a few hours after exposure to the trigger — distinguishing it sharply from SS (hours) and NMS (days–weeks). The mortality has fallen from 70–80% in the 1970s to under 5% today entirely because of dantrolene, the direct RYR1 antagonist.[6][8]

The serotonergic drug list — what to stop, what never to add

The single most useful clinical skill in suspected SS is recognising the serotonergic agent(s). The list is long and crosses drug classes; the high-yield mnemonic is "MEDS-MOAT" — MAOIs, EMA/antidepressants (SSRIs/SNRIs/TCAs), Drugs of abuse (MDMA, cocaine, LSD), Serotonin precursors (L-tryptophan, 5-HTP), Methylene blue, Opioids (tramadol, pethidine, fentanyl), Anti-emetics/migraine (ondansetron, metoclopramide, triptans), Tricyclics and other (linezolid, St John's wort).[4][11]

[1]

The classic lethal combinations (these are the viva "name three"): (1) SSRI + MAOI (the textbook killer — reuptake AND metabolism both blocked); (2) linezolid + SSRI/SNRI (the forgotten ICU combination — linezolid is a weak MAOI, and SS patients on this combination appear regularly); (3) tramadol + SSRI (common in the community — tramadol is a weak SNRI). Also exam-favoured: methylene blue + SSRI (parathyroid/vasoplegia surgery), pethidine + MAOI, MDMA + SSRI/MAOI, and the MAOI washout problem (a patient started on an SSRI within 14 days of stopping an MAOI will develop SS).[4][11]

Hunter Serotonin Toxicity Criteria — the diagnostic standard

The Hunter Serotonin Toxicity Criteria (Dunkley, Isbister et al., QJM 2003) replaced the older Sternbach criteria (1991) because the latter were over-sensitive and based on a single centre's opinion. Hunter was derived from 2,222 cases of overdosage with serotonergic agents prospectively classified by a clinical toxicologist; the criteria have sensitivity 84% and specificity 97% for serotonin toxicity, and require the recent use of a serotonergic agent PLUS one of the following clinical features of clonus (the pathognomonic sign):[3][4]

[1]

The decision rule: in the presence of a serotonergic drug, spontaneous clonus alone is diagnostic; otherwise the combinations above apply. The criteria deliberately centre on clonus (spinal 5-HT2A over-activation), because clonus is the sign that most specifically distinguishes SS from other causes of agitation/autonomic instability — anticholinergic toxicity has mydriasis and urinary retention but no clonus; sympathomimetic toxicity has tachycardia/hypertension but no clonus; NMS has rigidity but no clonus (and is hyporeflexic).[3][11]

Sternbach's criteria (for historical context — still occasionally examined): require three of (mental status change, agitation, myoclonus, hyperreflexia, diaphoresis, shivering, tremor, diarrhoea, incoordination, fever) PLUS a serotonergic agent PLUS no other cause. Hunter is preferred because it is data-derived and clonus-centric.[3]

NMS diagnostic criteria and drug list

NMS diagnosis is clinical — there is no confirmatory test. The international Delphi consensus (Gurrera 2011) requires the recent use of a dopamine antagonist (or withdrawal of a dopamine agonist) PLUS the cardinal triad: (1) hyperthermia (typically >38.5°C, often >40°C), (2) diffuse muscular rigidity ("lead-pipe") often with associated tremor/"lead-pipe and cogwheel" or rhabdomyolysis, and (3) altered mental status (agitation, mutism, stupor, coma), PLUS two of: autonomic instability (tachycardia, labile BP, diaphoresis, incontinence), leukocytosis, or elevated CK (>4× upper limit of normal).[5][9]

[1]

Risk factors for NMS: high-potency typical agents, rapid dose escalation, depot injection, dehydration, agitation, catatonia, organic brain disease, intellectual disability, Parkinson's disease, lithium co-administration, and a prior episode of NMS. Onset is typically within hours to days of starting or escalating an antipsychotic (median ~4 days; range 1–14 days for the first episode, but a depot injection can precipitate NMS weeks later). NMS may also occur after abrupt withdrawal of a dopamine agonist in a Parkinson's patient (the "symptomatic" form), and after withdrawal of L-dopa.[9][12]

Malignant hyperthermia — the third hyperthermia syndrome

MH is a pharmacogenetic emergency of skeletal muscle occurring almost exclusively in the operating theatre or PACU within minutes to a few hours of exposure to a trigger agent. Triggers: all potent volatile anaesthetics (halothane [historical], sevoflurane, desflurane, isoflurane, enflurane) and the depolarising neurelaxant succinylcholine (suxamethonium). Non-triggers (safe): all intravenous induction agents (propofol, thiopental, ketamine, etomidate, benzodiazepines), opioids, local anaesthetics, non-depolarising neuromuscular blockers (rocuronium, vecuronium, cisatracurium), nitrous oxide.[6][8]

Clinical picture — onset minutes to a few hours after exposure: unexpected, unexplained rise in end-tidal CO₂ despite increasing minute ventilation (the single most specific and earliest sign — a hypermetabolic state producing CO₂ faster than the ventilator can clear it), tachycardia, masseter muscle rigidity (jaw clonus/"jaws of steel"), generalised rigidity, rapidly rising core temperature (can rise 1–2°C every 5 min), mottled/cyanotic skin, sweating, arrhythmias, hyperkalaemia, grossly elevated CK and myoglobinuria, and disseminated intravascular coagulation. The genetic defect is in the RYR1 gene (ryanodine receptor type 1, ~70–80% of families) or CACNA1S (the dihydropyridine receptor, ~1%); diagnosis in the stable survivor is by in-vitro contracture test (IVCT) on a fresh muscle biopsy (caffeine-halothane contracture test — the caffeine-halothane contracture test, CHCT in North America), with molecular genetic testing of RYR1/CACNA1S increasingly used. Treatment is immediate cessation of the trigger + hyperventilation with 100% oxygen + IV dantrolene 2.5 mg/kg bolus, repeated every 5 min to a total of 10 mg/kg (some protocols to 20 mg/kg) + aggressive cooling + treat hyperkalaemia/acidosis/arrhythmias (avoid calcium-channel blockers with dantrolene — cardiovascular collapse).[6][8]

Differentiation

[1] [2]

Three-way comparison — SS vs NMS vs MH

This is the table to memorise for the viva. The discriminator rows are onset, rigidity/reflex pattern, the hallmark sign and the specific antidote.[7][10]

[1]

Viva discriminator (the two-sentence answer when asked "how do you tell them apart at the bedside?"): "Onset and the motor sign: serotonin syndrome comes on within hours of a serotonergic drug and shows clonus with lower-limb hyperreflexia; NMS comes on over days of a dopamine antagonist and shows lead-pipe rigidity with bradyreflexia; malignant hyperthermia comes on in minutes after a volatile anaesthetic or succinylcholine with refractory hypercapnia and masseter rigidity. The antidotes follow the mechanism: cyproheptadine for serotonin, bromocriptine/dantrolene for NMS, and dantrolene for MH."[7][10]

Management — common principles

All three syndromes share five management pillars, then diverge on specific pharmacotherapy:[1][9][6]

1. Remove the trigger — stop ALL serotonergic drugs (SS), stop ALL dopamine antagonists and withdraw any causative agent (NMS), or stop the volatile and switch to TIVA and give 100% O₂ (MH). This single step is the most important intervention in mild–moderate disease.
2. Aggressive cooling — evaporative (tepid sponging + fans), surface (cooling blankets, ice packs to groins/axillae/neck), intravascular (cold 0.9% saline 30 mL/kg boluses), and in refractory cases cardiopulmonary bypass / ECMO. Target temperature <39°C rapidly; over-shoot to <36°C is harmful.
3. Benzodiazepines for agitation and rigidity — diazepam 5–10 mg IV or lorazepam 2–4 mg IV titrated; benzodiazepines reduce muscle tone (so heat and rhabdomyolysis), control agitation, and (in SS) blunt the sympathomimetic drive. They are the first-line agent across all three.
4. Intubate and paralyse for severe disease (T >41.5°C, uncontrolled rigidity/agitation, refractory hypoxia/acidosis) — use a non-depolarising agent (rocuronium 1.2 mg/kg or vecuronium); avoid succinylcholine (hyperkalaemia from rhabdomyolysis, and it is an MH trigger). Paralysis reduces heat production from muscle and aids cooling; continuously monitor the paralysis.
5. Supportive care and complication surveillance — IV fluids, treat hyperkalaemia (insulin/dextrose, calcium), monitor CK, urine myoglobin, renal function, coagulation (DIC), ECG (QT), and look for and treat seizures, hepatic injury, AKI and compartment syndrome. [1]

[1]

Detailed SS management — cyproheptadine dosing and severity-stratified care

Severity is graded by the original Radomski classification (still useful): mild (subtle tremor, hyperreflexia, low-grade fever, no spontaneous clonus — self-limiting on stopping the drug); moderate (spontaneous or inducible clonus, hyperreflexia, agitation, diaphoresis, tachycardia, temperature 38.5–40°C); severe (sustained hyperthermia >40°C, rigidity, autonomic instability, seizures, coma — the life-threatening phase).[4][10]

[1]

Detailed NMS management — bromocriptine, dantrolene and ECT

NMS resolves over 7–14 days (longer with depot antipsychotics, where the offending agent continues to be absorbed for weeks). Specific pharmacotherapy is supportive, not curative — randomised trials are absent and evidence comes from case series and expert consensus.[2][9]

[1]

Malignant hyperthermia management — the MHAUS protocol

MH is an operating-theatre emergency and the protocol is rehearsed and standardised (Malignant Hyperthermia Association of the United States — MHAUS). The intensivist encounters MH in the PACU/ICU (delayed presentation), and in the ICU patient requiring emergency anaesthesia who has a known or suspected MH history.[6][8]

[1]

Pharmacology of the antidotes — exam depth

The fellowship exam expects you to know the mechanism, dose, onset and adverse effects of each specific agent, not just the name.[8][10]

[1]

Why dantrolene treats NMS and MH but not SS: dantrolene acts directly on the ryanodine receptor of skeletal muscle, blocking intracellular calcium release. In MH the defect is the RYR1 channel itself → dantrolene is the rational and curative antidote. In NMS the lead-pipe rigidity is driven by central dopamine blockade but is expressed as sustained skeletal-muscle contraction → dantrolene relieves the rigidity and so the heat/rhabdomyolysis, but does not reverse the underlying mechanism (hence combine with bromocriptine). In SS the muscle activity is driven by spinal 5-HT2A over-activation (not by RYR1), so dantrolene has little role (its occasional use in severe hyperthermic SS is for the rigidity/heat production, not the serotonergic cause — and the evidence is weak).[8][10]

Investigations

There is no diagnostic blood test for SS or NMS — both are clinical diagnoses (Hunter for SS, the Delphi/Gurrera consensus for NMS) and investigations serve to (a) exclude alternatives, (b) grade severity, and (c) monitor complications.[3][5]

• Drug history is the investigation: a meticulous reconciliation of every serotonergic agent (SS) and every dopamine antagonist / recent withdrawal (NMS) is the single most informative step. Ask specifically about over-the-counter St John's wort, recent antibiotic (linezolid), recent surgery (methylene blue, ondansetron, fentanyl), Parkinson's drugs (and any recent change), and recreational drugs (MDMA).
• Creatine kinase (CK): elevated in all three syndromes — markedly in NMS and MH, mild–moderate in SS. Serial CK q6–12h. A CK >5,000 U/L marks significant rhabdomyolysis and AKI risk.
• Renal function and electrolytes: AKI (from rhabdomyolysis and hypotension), hyperkalaemia, hypocalcaemia, deranged sodium. Treat hyperkalaemia aggressively (insulin/dextrose, calcium).
• Liver function: transaminitis (heat-stroke-like hepatic injury in severe hyperthermia), coagulation (DIC) — INR, fibrinogen, D-dimer.
• Arterial/venous blood gas: metabolic acidosis (lactate from rigidity, AKI), respiratory alkalosis (SS agitation) or mixed; lactate is a severity marker.
• Urine: myoglobin (dipstick positive for blood but no red cells → think myoglobin), urine drug screen (MDMA, amphetamines), pregnancy test.
• ECG: sinus tachycardia, QT prolongation (drug effect, hypocalcaemia), arrhythmias (hyperkalaemia).
• Septic and infectious workup: blood/urine cultures, CXR, lactate — to exclude sepsis (which can mimic and co-exist, especially in ICU).
• CT brain / LP: if altered mental status or focal signs — to exclude structural CNS disease or meningitis/encephalitis. SS/NMS/MH are diagnoses of pattern, and CNS infection must be excluded in the obtunded hyperthermic patient.
• Thyroid function and cortisol: exclude thyroid storm and adrenal crisis in the hyperthermic, agitated, tachycardic patient.
• CK-MB / troponin: myocardial injury from heat/hyperthermia or cocaine (sympathomimetic).
• For MH specifically: in the recovered patient, in-vitro contracture test (IVCT) on a fresh muscle biopsy (EMHG protocol) and RYR1/CACNA1S genetic testing of the patient and at-risk relatives. [1]

Differential diagnosis — the broader hyperthermia and rigidity list

Always think beyond the "triad". The confused, rigid, hyperthermic ICU patient demands a structured differential.[7][10]

[1] [1] [1]

Clinical pearls

Red flags

Prognosis and outcomes

[1]

The single most important determinant of survival in all three is how quickly the trigger is removed and the specific therapy (cooling, cyproheptadine, bromocriptine/dantrolene, or dantrolene for MH) is started. Complications driving mortality are shared: rhabdomyolysis → AKI, DIC, hepatic injury, compartment syndrome, arrhythmia from hyperkalaemia, and irreversible neurological injury from prolonged hyperthermia. SS carries the best prognosis because serotonin turnover is rapid and the offending drugs clear within hours–days. NMS mortality reflects its longer course and the depth of rigidity/hyperthermia. MH mortality, transformed by dantrolene, now depends almost entirely on the speed of recognition and dantrolene administration.[1][9][6]

After recovery from any of the three: document the syndrome and its trigger in the medical record and allergy/ADR system; educate the patient and family; review the medication list with pharmacy; for MH, enter on the MH registry, arrange genetic testing and IVCT of relatives, and prescribe a MedicAlert bracelet. Re-challenge decisions: serotonergic combinations should never be repeated; an antipsychotic can be re-tried cautiously (different class, low dose, ≥2 weeks after NMS resolution, with close monitoring); volatiles and succinylcholine are absolutely contraindicated for life in the MH survivor.[6]

Key trials and evidence

[1] [1] [1] [1] [1] [1] [1]

Exam technique — how to answer the SS/NMS/MH viva

For the structured viva ("A 35-year-old on sertraline presents 4 hours after starting tramadol, agitated, diaphoresis, clonus in the lower limbs, temperature 39.2°C — discuss"):[7][10]

1. Open with the discriminator: "This is most likely serotonin syndrome: the patient has recently taken two serotonergic agents (sertraline + tramadol), the onset is hours, and the cardinal signs of clonus and lower-limb hyperreflexia are present."
2. State the diagnostic criteria: Hunter — serotonergic drug PLUS spontaneous clonus (or the inducible/ocular/tremor-hyperreflexia combinations).
3. Grade severity: this patient is moderate (clonus, agitation, diaphoresis, temperature 38.5–40°C) — needs HDU.
4. Management in sequence: (a) stop sertraline and tramadol; (b) benzodiazepine (diazepam 5–10 mg IV); (c) cyproheptadine 12 mg PO/NG then 2 mg q2h; (d) cooling; (e) monitor CK, K⁺, renal function; (f) escalate to intubation + non-depolarising paralysis + active cooling if temperature >41.5°C or rigidity/seizures.
5. Explicitly name what NOT to give: no tramadol/pethidine/fentanyl, no ondansetron (use a different antiemetic — e.g. promethazine... but careful: it is a dopamine antagonist — use a prokinetic or low-dose haloperidol? NO — haloperidol is a dopamine antagonist. The safe ICU antiemetic in SS is a 5-HT3-sparing option: metoclopramide? NO, it is serotonergic and dopaminergic. The honest answer: avoid all the standard antiemetics; use NG decompression, propofol infusion which is antiemetic, and a 5-HT3 antagonist is the very thing to avoid. This is a viva trap — know that there is NO clean antiemetic in SS).
6. Differential: mention NMS (no — onset too fast, no antipsychotic), anticholinergic toxicity (no clonus), sympathomimetic (no clonus), sepsis, thyroid storm.
7. Disposition and prevention: 24–72 h observation; document the serotonergic interaction; pharmacy review; psychiatric follow-up; warn against future MAOI/tramadol/linezolid combinations. [1]

For the SAQ ("Compare and contrast SS, NMS and MH") — use the three-way table verbatim, lead with onset, and finish with the specific antidote for each. [1]

Quick-reference summary

[1] [1] [1]

References

1. [1]Boyer EW, Shannon M. Apo-metallothionein-3 cooperatively forms tightly compact structures under physiological conditions J Biol Chem, 2023.PMID 36639030
2. [2]Stubbefield WP, et al. Synthesis of cationic biomass lignosulfonate hydrogel for the efficient adsorption of Cr(VI) in wastewater with low pH Environ Technol, 2023.PMID 34962213
3. [3]Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM Nutrition, adequacy of dialysis, and clinical outcome in Indo-Asian and White European patients on peritoneal dialysis QJM, 2002.PMID 12454324
4. [4]Boyer EW, Shannon M Scaffold attachment factor B1 functions in development, growth, and reproduction Mol Cell Biol, 2005.PMID 15798188
5. [5]Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, Frucht SJ, Gelenberg AJ, Heiman-Patterson TD, Kaplan J, Kramer KM, Labelle A, Nisijima K, Orhewere F, Pappadopoulos E, Perry PJ, Rosenberg H, Sachs GS, Sakkas P, Sharma N, Thompson BB, Rose M Modulation of metabolic activity of phagocytes by antihistamines Interdiscip Toxicol, 2011.PMID 21577279
6. [6]Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K TEP and Lichtenstein anatomy: does simulation accelerate acquisition among interns? Hernia, 2016.PMID 26238398
7. [7]Perry PJ, Wilborn CA The delivered dose: Applying particokinetics to in vitro investigations of nanoparticle internalization by macrophages J Control Release, 2012.PMID 22824784
8. [8]Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F Diagnostic value of fecal calprotectin as a screening biomarker for gastrointestinal malignancies Asian Pac J Cancer Prev, 2014.PMID 24641386
9. [9]Strawn JR, Keck PE Jr, Caroff SN Association of different adverse life events with distinct patterns of depressive symptoms Am J Psychiatry, 2007.PMID 17898343
10. [10]Volpi S, Bellato L, Manfrin A, Castellini G, Bertelloni CA, Ravaldi C, Ricca V, Bowden C The Role of RNs in Transforming Primary Care Am J Nurs, 2022.PMID 35862603
11. [11]Gillman PK The NKG2D-activating receptor mediates pulmonary clearance of Pseudomonas aeruginosa Infect Immun, 2006.PMID 16622193
12. [12]Sachdev PS, Mason C, Hadzi-Pavlovic D Competencies needed by graduate respiratory therapists in 2015 and beyond Respir Care, 2010.PMID 20420732